RoActemra (tocilizumab) licensed for systemic juvenile idiopathic arthritis

The RoActemra dose for children is calculated by weight and given by intravenous infusion every 2 weeks
The RoActemra dose for children is calculated by weight and given by intravenous infusion every 2 weeks

The IL-6-inhibiting antibody tocilizumab (RoActemra) can now be used to treat active systemic juvenile idiopathic arthritis (sJIA) in children 2 years of age and above when the response to NSAIDs and systemic corticosteroids is inadequate. It can be given in combination with methotrexate or as monotherapy when methotrexate is inappropriate or not tolerated.

Clinical study

In the randomised, double-blind TENDER study (n=112), significantly more children treated with tocilizumab achieved the primary endpoint (≥30% reduction in JIA ACR core set score and absence of fever) at week 12 compared with children who received placebo: 85% (64/75) versus 24% (9/37), respectively (p<0.0001).

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more